Targets › DLL3
18 programs from 15 companies in 63 trials: 33 Phase 1, 19 Phase 2, 11 Phase 3; Oncology; next expected readout Nov 2026.
Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. (UniProt, Q9NYJ7)
Open in Phaseline: the race on DLL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Daiichi Sankyo | Ifinatamab deruxtecan (DS-7300a, I-DXd) Anti-B7H3 antibody-drug conjugate | B7H3, DLL3 | Phase 3 | Small Cell Lung Cancer; Esophageal Squamous Cell Carcinoma; Extensive-stage Small-cell Lung Cancer; Advanced Solid Tumor … | Dec 2026 |
| Boehringer Ingelheim | Obrixtamig DLL3-targeting antibody-drug conjugate | DLL3 | Phase 3 | Small Cell Lung Cancer (SCLC); Extrapulmonary Neuroendocrine Cancer (epNEC); Small Cell Lung Carcinoma (SCLC); Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 … | Mar 2027 |
| Amgen | Tarlatamab T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent | CD3E, CD3G, CD3D, DLL3 | Phase 3 | Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Small-cell Lung Cancer; Extensive-Stage Small-Cell Lung Cancer … | Apr 2027 |
| AbbVie | ABBV-706 Delta-like ligand 3 (DLL3) targeted therapy | DLL3 | Phase 3 | Small Cell Lung Cancer; Advanced Solid Tumors | Nov 2027 |
| Boehringer Ingelheim | BI 764532 DLL3-targeting antibody-drug conjugate | DLL3 | Phase 2 | Small Cell Lung Carcinoma; Small Cell Lung Carcinoma (SCLC); Glioma; Neuroendocrine Neoplasms | Dec 2026 |
| Tingting Yuan | [⁶⁸Ga]Ga-PFD3 DLL3-targeting PET tracer; nanobody conjugate with ⁶⁸Ga radiolabel | DLL3 | Phase 2 | Neuroendocrine Tumors | Dec 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | GC511B CAR-T Cell Injection Anti-DLL3 CAR-T cell therapy | DLL3 | Phase 1 | Relapsed/Refractory Small Cell Lung Cancer | Nov 2026 |
| Sichuan University | α-PD-L1/4-1BB DLL3 CAR-T (BHP01) dual-targeted CAR-T cell therapy targeting PD-L1 and DLL3 with 4-1BB costimulatory domain | CD274, DLL3 | Phase 1 | Small Cell Lung Cancer Extensive Stage | Dec 2026 |
| Abdera Therapeutics | 225Ac-ABD147 DLL3-targeting antibody fragment conjugated with actinium-225 | DLL3 | Phase 1 | Small-Cell Lung Cancer (SCLC) | Jan 2027 |
| Beijing Biotech | EB-DART-NK01 Allogeneic dual-target CAR-NK cells (DLL3/CD56, DLL3/GD2, or CD56/GD2) | DLL3, CD56, GD2 | Phase 1 | Small Cell Lung Cancer (SCLC) | Feb 2027 |
| Phanes Therapeutics | Peluntamig (PT217) Bispecific antibody against DLL3 and CD47 | DLL3, CD47 | Phase 1 | Small Cell Lung Cancer (SCLC) | Dec 2027 |
| Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Gocatamig (HPN328, MK-6070) DLL3-targeted trispecific antibody | DLL3 | Phase 1 | Small-Cell Lung Cancer | Jan 2028 |
| Molecular Partners | [212Pb]Pb-MP0712 DLL3-targeting radioligand therapy (alpha particle emitter) | DLL3 | Phase 1 | Large Cell Neuroendocrine Carcinoma | Sep 2028 |
| IDEAYA Biosciences | IDE849 DLL3-targeted bispecific antibody | DLL3 | Phase 1 | Small-cell Lung Cancer | Jul 2029 |
| Memorial Sloan Kettering Cancer Center | DLL3-SAVVYZ-IL18 CAR T cell DLL3-targeting CAR T cell with IL-18 enhancement | DLL3 | Phase 1 | Neuroendocrine Cancer | Aug 2029 |
| Novartis | DJI136 DLL3-targeted CAR-T therapy | DLL3 | Phase 1 | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Mar 2031 |
| Novartis | [111In]In-ETN029 Indium-111 labeled imaging agent targeting DLL3 | DLL3 | Phase 1 | Small Cell Lung Carcinoma | Aug 2031 |
| Novartis | [225Ac]Ac-ETN029 Alpha-emitting radioligand targeting DLL3 | DLL3 | Phase 1 | Small Cell Lung Carcinoma | Aug 2031 |
Small Cell Lung Cancer (7) Small Cell Lung Cancer (SCLC) (6) Extensive Stage Small Cell Lung Cancer (4) Small Cell Lung Carcinoma (4) Small Cell Lung Carcinoma (SCLC) (4) Small-cell Lung Cancer (3) Relapsed/Refractory Small Cell Lung Cancer (2) Glioma (2) Esophageal Squamous Cell Carcinoma (1) Extensive-stage Small-cell Lung Cancer (1) Advanced Solid Tumor (1) Extensive Stage-small Cell Lung Cancer (1)
small molecule (6), mixed (5), antibody (3), other (3), protein or peptide (1)
Novartis (3) Boehringer Ingelheim (2) Daiichi Sankyo (1) Amgen (1) Molecular Partners (1) AbbVie (1) IDEAYA Biosciences (1) Beijing Biotech (1) Phanes Therapeutics (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Memorial Sloan Kettering Cancer Center (1) Sichuan University (1) Abdera Therapeutics (1) Tingting Yuan (1) Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
B7H3 (1) CD3E (1) CD3G (1) CD3D (1) CD56 (1) GD2 (1) CD47 (1) CD274 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.